medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2014, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2014; 59 (3)

Carta al editor

Serrano OJA, Zempoalteca LAM, Gerson CR

Language: Spanish
References: 12
Page: 231-233
PDF size: 113.37 Kb.


Text Extraction

No abstract


REFERENCES

  1. López-Velarde PT, López-Velarde BP. Prevención y tratamiento de cardiotoxicidad en pacientes con cáncer. Anales Médicos. 2014; 59: 54-60.

  2. Curigliano G, Cardinale D, Suter T et al. Cardiovascular toxicity induced by chemotherapy targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 (suppl. 7): VII 155-VII 166.

  3. Slamon DJ, Leyland B, Shak S et al. Use of chemotherapy plus of a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.

  4. Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res. 2008; 109: 231-239.

  5. Moja L, Tagliabue L, Balduzzi S et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012; 18: 1-81.

  6. Chavez-MacGregor M, Zhang N, Buchholtz T et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013; 33: 4222-4228.

  7. Romond EH, Pérez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-184.

  8. Gallegos CS, Cárdenas CR, Aldaco SF et al. Guías para la prevención de la cardiotoxicidad en oncología y hematología. GAMO. 2009; 8 (suppl. 3): 1-90.

  9. Serrano A. Estrategias de cardioprotección: ¿mantienen la efectividad de la quimioterapia? GAMO. 2009; 8 (suppl. 3): 13-19.

  10. Vrooman ML, Neuberg SD, Stevsenson EK et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Can. 2011; 47: 1373-1379.

  11. Walker DM, Fisher BT, Seif AE et al. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the pediatric health information systems database. Pediatr Blood Cancer. 2013; 60: 616-620.

  12. Hedhli N, Rusell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev. 2011; 7: 221-233.




2020     |     www.medigraphic.com